VIDEO: Microbiota-based biotherapeutic demonstrates superiority in C. difficile treatment
In a video exclusive, Paul Feuerstadt, MD, FACG, AGAF, Yale University School of Medicine, tells Healio Gastroenterology about new study data regarding investigational biotherapeutic RBX2660 for the treatment of Clostridioides difficile.
“RBX2660 provides us with a beacon of hope that the FDA will approve a product like this and that, what we saw in March and April 2020, will never happen again,” Feuerstadt concluded. “Knowing that we have treatments available ... has really led to comfort I think clinically, utilizing this product to reduce rates of recurrence of this devastating impact.”
Collapse
Feuerstadt P, et al. Poster Sa611. Presented at: Digestive Disease Week; May 21-23 (virtual meeting).
Read more about